ArticleJournal of mass spectrometry and advances in the clinical lab2025
A non-affinity-dependent high-resolution mass spectrometry method for detecting and typing monoclonal free light immunoglobulin chains.
Article in Journal of mass spectrometry and advances in the clinical lab, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Detecting and monitoring monoclonal free light immunoglobulin chains in serum is important for managing patients with B-cell neoplasms. Established methods have relied on immunochemistry, with monoclonality determined through an abnormal ratio of free kappa and lambda chains and an increased concentration of the involved chain. This indirect approach has limitations. Mass spectrometric methods that directly demonstrate the monoclonal fraction have been described; however, all reported approaches so far are affinity-dependent. The aim of this study was to develop a non-affinity-dependent high-resolution mass spectrometry (HRMS) method. Methods: Samples were prepared using ultrafiltration, then separated by reversed-phase liquid chromatography and analyzed by HRMS. The performance of the method was evaluated, including a comparison with a nephelometric immunoassay for free light immunoglobulin chains. Results: Concordance between HRMS and the immunoassay in classifying a sample as containing a monoclonal free light chain or not was 84% (based on 100 unique patient samples). HRMS identified more samples containing a monoclonal free light chain than the immunoassay. Some monoclonal fractions were glycosylated and/or cysteinylated. Imprecision (CV) for the concentration measurements of monoclonal fractions ranged from 10 to 14%. Conclusions: The HRMS method presented can detect, isotype, and semi-quantify monoclonal monomeric and dimeric light chains in serum, as well as demonstrate post-translational modifications. It is a selective, non-affinity-dependent method with a simple workflow that has the potential to become a valuable tool in the management of B-cell diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.